Skip to content

Research at St Andrews

43 The role of mechanically-supported emergency percutaneous coronary intervention in cardiogenic shock

Research output: Contribution to journalArticlepeer-review

Author(s)

Kristina Frain, Paul Rees

School/Research organisations

Abstract

Background Historically, the intra-aortic balloon pump (IABP) has been the primary means of providing rapid mechanical circulatory support (MCS) in patients undergoing emergency revascularisation for acute myocardial infarction complicated by cardiogenic shock (AMI-CS). Despite the availability of alternative devices such as the percutaneous Impella 2.5/CP® which have displayed superior haemodynamic support in animal models, evidence in support of their use in humans is limited and international guidelines do not currently recommend their use. This review aims to examine the existing literature in order to compare survival outcomes in AMI-CS patients undergoing emergent revascularisation supported by percutaneous MCS devices; IABP and Impella 2.5/CP, to discuss the implications of the findings on clinical practice.Method A review of the literature was conducted through the application of search terms ‘Intra-aortic balloon pump’, ‘Impella’, ‘Cardiogenic shock’ and ‘Mortality’ to four databases: Ovid Medline, Ovid Embase, Cochrane and Web of Science. This resulted in 1,823 studies which were then screened based on title and abstract before full text analysis to identify studies that met pre-defined inclusion and exclusion criteria.Results 12 studies met the eligibility criteria: 2 randomised controlled trials (RCTs) and 10 observational studies. In total 28,104 patients were included. 10 studies compared outcomes in patients treated with IABP compared to control. Only 2 studies directly compared outcomes in patients supported by the IABP vs Impella®. The results were inconsistent. 10/12 studies found no difference in mortality between intervention and control arms. Notably, one study claimed reduced mortality with IABP vs control, and one study concluded that Impella® improved survival rates when compared to IABP. The average 30-day all-cause mortality in patients treated with IABP was 42.57® which is consistent with historical studies.Conclusion AMI-CS represents an important cohort of patients in whom conducting RCTs is difficult. As a result, the literature is limited. Analysis of the studies available suggests that there is insufficient evidence to support superior survival in those supported by IABP or Impella® when compared to control. Despite noting positive findings in terms of demonstratable haemodynamic support associated with the Impella® in porcine models these benefits have not been observed in human studies. This literature review failed to establish superior survival associated with the use of IABP or the Impella®, however limitations of the studies have been discussed to outline suggestions for future research.Conflict of Interest None
Close

Details

Original languageUndefined/Unknown
Pages (from-to)A36-A36
JournalHeart
Volume106
Issue numberSuppl 2
DOIs
Publication statusPublished - 2020

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. The REBOA window: a cadaveric study delineating the optimum site for austere cannulation of the femoral artery for resuscitative endovascular balloon occlusion of the aorta

    Slim, N., West, C. T., Rees, P., Brassett, C. & Gaunt, M., 2 Mar 2020, In: BMJ Military Health.

    Research output: Contribution to journalArticlepeer-review

  2. Military application of mechanical CPR devices: a pressing requirement?

    Parsons, I. T., Cox, A. T. & Rees, P., Nov 2018, In: Journal of the Royal Army Medical Corps. 164, 6, p. 438-441

    Research output: Contribution to journalArticlepeer-review

  3. An observational study of clinical outcomes of everolimus-eluting bioresorbable scaffolds comparing the procedural use of optical coherence tomography against angiography alone

    Hamshere, S., Byrne, A., Guttmann, O., Rees, P., Weerakody, C., Wragg, A., Knight, C., Mathur, A. & Jones, D. A., 1 Sep 2018, In: Coronary Artery Disease. 29, 6, p. 482-488

    Research output: Contribution to journalArticlepeer-review

Related by journal

  1. No association between systemic arteriosclerosis and atherosclerosis on cardiac MRI and whole body MR angiography: the TASCFORCE study

    Weir-McCall, J., Lambert, M., Belch, J., Cavin, I., Gandy, S., Littleford, R., Macfarlane, J., Matthew, S., Nicholas, R. S., Struthers, A. D., Sullivan, F., Henderson, S., White, R. & Houston, J. G., 18 May 2017, In: Heart. 103, Suppl 4, p. A5-A6 15.

    Research output: Contribution to journalAbstractpeer-review

  2. Targeted Resuscitation Using Echocardiography in a Deployed Military Ebola Virus Disease Treatment Unit

    Rees, P., Jun 2015, In: Heart. p. 1 127 p., 101.

    Research output: Contribution to journalArticlepeer-review

  3. 117 ECHOCARDIOGRAPHY, PERFORMED DURING DAMAGE CONTROL RESUSCITATION, CAN BE USED TO MONITOR THE HAEMODYNAMIC RESPONSE TO VOLUME INFUSION IN THE DEPLOYED MILITARY CRITICAL CARE UNIT

    Rees, P. S. C., Inwald, D. P. & Hutchings, S. D., 2013, In: Heart. 99, suppl 2, p. A71

    Research output: Contribution to journalArticlepeer-review

  4. 014 Atorvastatin protects human myocardium from lethal ischaemia-reperfusion injury by activating the risk pathway

    Rees, P. S. C., Babu, G. G., Boston-Griffiths, E. A., Bognolo, G., Hayward, M., Kolvekar, S., Lawrence, D., Yap, J., Hausenloy, D. J. & Yellon, D. M., 2010, In: Heart. 96, Suppl 1, p. A11

    Research output: Contribution to journalArticlepeer-review

ID: 269246373

Top